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Abstract
Microdialysis is a minimally invasive technique often paired with laser Doppler flowmetry to examine cutaneous 
microvascular function, yet presents with several challenges, including incompatibility with perfusion of highly 
lipophilic compounds. The present study addresses this methodological concern, with an emphasis on the 
independent effects of commonly used vehicle dialysis solutions to improve solubility of pharmacological agents 
with otherwise low aqueous solubility. Four microdialysis fibers were placed in the ventral forearm of eight subjects 
(4 men, 4 women; 25±1 yr) with sites randomized to serve as 1) control (lactated Ringer’s), 2) Sodium carbonate-
bicarbonate buffer administered at physiological pH [SCB-HCl; pH 7.4, achieved via addition of hydrochloric acid 
(HCl)], 3) 0.02% ethanol, and 4) 2% dimethyl sulfoxide (DMSO). After baseline (34°C), vehicle solutions were 
administered throughout a standardized local heating protocol to 42°C. Laser Doppler flowmetry provided an 
index of blood flow. Cutaneous vascular conductance was calculated and normalized to maximum (%CVCmax, 
sodium nitroprusside and 43°C local heat). The SCB-HCl solution increased baseline %CVCmax (control: 9.7± 0.8; 
SCB-HCl: 21.5±3.5%CVCmax; P = 0.03), but no effects were observed during heating or maximal vasodilation. 
There were no differences with perfusion of ethanol or DMSO at any stage of the protocol (P > 0.05). These data 
demonstrate the potential confounding effects of some vehicle dialysis solutions on cutaneous vascular function. 
Notably, this study provides evidence that 2% DMSO and 0.02% ethanol are acceptable vehicles with no 
confounding local vascular effects to a standardized local heating protocol at the concentrations presented.
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Smith CJ, Craighead DH, Alexander LM. Effects of vehicle
microdialysis solutions on cutaneous vascular responses to local
heating. J Appl Physiol 123: 1461–1467, 2017. First published August
31, 2017; doi:10.1152/japplphysiol.00498.2017.—Microdialysis is a
minimally invasive technique often paired with laser Doppler flow-
metry to examine cutaneous microvascular function, yet presents with
several challenges, including incompatibility with perfusion of highly
lipophilic compounds. The present study addresses this methodolog-
ical concern, with an emphasis on the independent effects of com-
monly used vehicle dialysis solutions to improve solubility of phar-
macological agents with otherwise low aqueous solubility. Four mi-
crodialysis fibers were placed in the ventral forearm of eight subjects
(4 men, 4 women; 25  1 yr) with sites randomized to serve as 1)
control (lactated Ringer’s), 2) Sodium carbonate-bicarbonate buffer
administered at physiological pH [SCB-HCl; pH 7.4, achieved via
addition of hydrochloric acid (HCl)], 3) 0.02% ethanol, and 4) 2%
dimethyl sulfoxide (DMSO). After baseline (34°C), vehicle solutions
were administered throughout a standardized local heating protocol to
42°C. Laser Doppler flowmetry provided an index of blood flow.
Cutaneous vascular conductance was calculated and normalized to
maximum (%CVCmax, sodium nitroprusside and 43°C local heat).
The SCB-HCl solution increased baseline %CVCmax (control: 9.7 
0.8; SCB-HCl: 21.5  3.5%CVCmax; P  0.03), but no effects were
observed during heating or maximal vasodilation. There were no
differences with perfusion of ethanol or DMSO at any stage of the
protocol (P  0.05). These data demonstrate the potential confound-
ing effects of some vehicle dialysis solutions on cutaneous vascular
function. Notably, this study provides evidence that 2% DMSO and
0.02% ethanol are acceptable vehicles with no confounding local
vascular effects to a standardized local heating protocol at the con-
centrations presented.
NEW & NOTEWORTHY This study examined the independent
effects of common vehicle solutions on cutaneous vascular responses.
A basic buffer (SCB-HCl) caused baseline vasodilation; 2% DMSO
and 0.02% ethanol had no effects. This highlights the need for
considering potential confounding effects of solubilizing solutions
when combined with low aqueous soluble pharmacological agents.
Importantly, DMSO and ethanol do not appear to influence cutaneous
vascular function during baseline or local heating at the concentra-
tions studied, allowing their use without confounding effects.
microdialysis; solubility; laser Doppler flowmetry; vehicle solution;
skin blood flow
THE CUTANEOUS CIRCULATION is an accessible microvascular bed
that allows for in vivo assessment of cutaneous vascular
function and elucidation of mechanisms of vascular control.
Microdialysis is a minimally invasive technique that is com-
monly paired with laser Doppler flowmetry, as an index of skin
blood flow (SkBF), to deliver specific pharmacological agents
directly to the intradermal space without exerting any systemic
effects (10). This approach has been successfully utilized to
pharmaco-dissect a variety of signaling pathways involved in
cutaneous vascular control. Multiple disease groups, including,
primary aging (25), hypertension (8), hypercholesterolemia
(34), Type 2 diabetes (38), and heart failure (23), have been
studied, helping advance our knowledge of underlying vascular
dysfunction in these groups. This approach has been widely
adopted because alterations in cutaneous microvascular func-
tion mirror and often precede alterations in microvascular
function in other organs and tissues in both mechanism and
magnitude (13, 35).
The development and availability of pharmacological agents
utilized for pharmaco-dissection of signaling pathways in-
volved in cutaneous microvascular control has grown rapidly
with this area of study. To facilitate delivery to the cutaneous
circulation via intradermal microdialysis, pharmacological
agents are mixed with a vehicle solution and perfused through
microdialysis fibers. Lactated Ringer’s, a mixture of sodium
chloride, sodium lactate, potassium chloride, and calcium chlo-
ride in water, is the most common vehicle used for delivery of
water-soluble pharmacological agents via intradermal micro-
dialysis and often serves as a control solution when perfused
alone. However, the low aqueous solubility of some pharma-
cologics presents a significant obstacle in effective drug deliv-
ery, necessitating the use of other vehicle additives, such as
alcohols, acids, and bases, to improve solubility. Investigators
must therefore carefully consider the independent effects of
such vehicle solutions, the drug concentration achievable, and
the use of appropriate control sites and data normalization
strategies when appropriate.
The most commonly utilized solubilizing agents include
ethanol, dimethyl sulfoxide (DMSO), glycerol, and propylene
glycol, with varying concentrations depending on the specific
drug of interest. The two most widely used vehicle solutions
for nonaqueous pharmacologics delivered via cutaneous mi-
crodialysis are ethanol and DMSO, yet limited data have been
presented on the independent effects of these vehicles. A small
number of studies report pilot experiment data suggesting these
vehicles cause baseline vasodilation, but their effects during
experimental protocols have largely not been considered. In
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particular, DMSO has consistently been reported to cause
baseline vasodilation, but the use of concentrations ranging
from 0.1 to 5% has caused varying degrees of baseline shift
(31, 33, 36).
Whereas some pharmacologics have poor solubility in aque-
ous solutions, others require preparation in a basic buffer
solution to ensure stability and are returned to physiological pH
immediately before delivery [i.e., the prostacyclin I2 (PGI2)
agonist epoprostenol sodium is prepared and stored at
pH 10.2, and hydrogen sulfide donors (Na2S, NaHS, pH 
11)]. Sodium carbonate-bicarbonate (SCB) buffers are simple
to prepare, relatively inexpensive, and provide good stability,
making them an ideal and commonly used buffer for pharma-
logics requiring a basic solution. To avoid painful delivery into
the cutaneous circulation and local pH shifts, hydrochloric acid
is used to reduce the vehicle pH before administration. Despite
the increasing utilization of drug delivery via intradermal
microdialysis, the independent effects of such agents on cuta-
neous vascular function have not been determined. This raises
an important concern in studies that utilize solubilizing and
stabilizing agents, which may potentially confound SkBF re-
sponses if the effects of the vehicle solution are not taking into
consideration. Accordingly, the primary aim of this study was
to determine the independent effects of three widely used
vehicle solutions on cutaneous microvascular function during a
commonly utilized (5, 18, 24, 46) standard local heating (LH)
protocol to 42°C. Based on observations reported by other
authors and preliminary data from our laboratory (Unpublished
data; Clarke MM and Smith CJ 2016; Kutz JL and Alexander
LM 2016; Craighead DH; Alexander LM 2015), we hypothe-
sized that the SCB buffer with hydrochloric acid (pH 7.4) and
the 2% DMSO would cause vasodilation during both baseline
and the LH plateau, while 0.02% ethanol would not signifi-
cantly affect SkBF at any point during the protocol.
METHODS
The study was approved by the institutional review board at The
Pennsylvania State University and conformed to the guidelines set
forth in the Declaration of Helsinki. Written and verbal consent was
voluntarily obtained from all subjects before participation in the study.
The experiment was conducted in a group of eight young, healthy
participants who were nonsmokers, not pregnant or breastfeeding, and
were free from any known cardiovascular or metabolic diseases.
Women were tested regardless of menstrual cycle phase or use of birth
control. Participants were not taking any other medications that are
known to alter metabolic or vascular function.
All experiments took place in a thermoneutral laboratory with
subjects in a semisupine position. Subjects refrained from consuming
alcohol and caffeine, and from exercise, for 12 h before the study. On
arrival at the laboratory, subjects completed a medical history and
underwent measurements of anthropometrics, blood pressure, and
heart rate. All women participants had a negative urine pregnancy test
on the morning of the experiment. After screening, four intradermal
microdialysis fibers (30 kDa cutoff; MD 2000, LM-10, Bioanalytical
Systems) were placed in the skin of the ventral surface of the forearm
as previously described (40). After microdialysis fiber placement,
lactated Ringer’s solution was perfused through all sites at a rate of 2
l/min (BASi Bee Hive controller and Baby Bee syringe drive) for
60–90 min to allow full resolution of hyperemia due to fiber insertion
trauma.
After subsidence of hyperemia, LH units (Moor Instruments, UK)
were placed over all microdialysis sites and skin temperature was
clamped at 34°C to maintain thermoneutral baseline skin temperature.
Each LH unit housed a laser Doppler flowmeter probe (Moor Instru-
ments) for the continuous measurement of red cell flux, providing an
index of SkBF. Subjects were outfitted with an automated blood
pressure cuff (Cardiocap 5, General Electric), and blood pressure was
measured via brachial auscultation every 5 min throughout the pro-
tocol.
Baseline data were obtained for 10 min (baseline 1) before the
solution vehicles were randomly assigned to each microdialysis site,
including 1) lactated Ringer’s to serve as control (Owens and Minor),
2) 0.02% ethanol, 3) 2% dimethyl sulfoxide (DMSO), and 4) sodium
carbonate/sodium bicarbonate  hydrochloric acid [SCB-HCl: a so-
dium carbonate/sodium bicarbonate buffer solution (pH 10.4) was
mixed and then returned to physiological pH with hydrochloric acid].
All solution vehicles were perfused at a rate of 2 l/min for a
minimum of 20 min before obtaining a second “vehicle baseline”
(baseline 2), ensuring a stable plateau in SkBF was achieved. A
standardized LH protocol was employed in which the temperature of
the local heating units were raised to 42°C at a rate of 0.5°C/5 s. This
protocol is known to induce vasodilation that is predominantly de-
pendent on nitric oxide (NO) produced via endothelial NO synthase
(eNOS) (5, 30, 32) and is commonly utilized to assess cutaneous
microvascular function (1, 15, 21, 24, 39, 43). Local skin temperature
(Tsk) was clamped at 42°C, and SkBF measured until a stable “local
heating plateau” in SkBF was achieved (~40 min), after which the
local heaters were increased to 43°C, and 28 mM sodium nitroprus-
side (SNP) was perfused through each fiber at a rate of 4 l/min to
elicit maximum cutaneous vasodilation (5, 26).
In conjunction with our in vivo functional analysis, the ionic
compositions of all vehicle solutions were analyzed with an auto-
mated electrolyte analyzer (Diamond Diagnostics SmartLyte Electro-
lyte Analyzer) to determine sodium, potassium, and chloride concen-
trations. After completion of in vivo experiments, vehicle samples
were prepared in the exact same manner as for the functional exper-
iments and samples were analyzed in triplicate.
Data and statistical analysis. Red cell flux data were sampled at 40
Hz with WinDaq data acquisition software (DATAQ Instruments) and
stored offline for later analysis. Red cell flux was normalized to
cutaneous vascular conductance (CVC: flux per mean arterial pres-
sure) and expressed as a percentage of site specific maximum
(%CVCmax) obtained from perfusion of SNP and 43°C heat. Presen-
tation and interpretation of data as a percentage of maximum dilation
is standard when evaluating cutaneous microvascular function since it
reduces variability due to the heterogeneous distribution of microves-
sels within skin tissue (3, 4).
All data were analyzed with SAS version 9.3 software. One-way
ANOVAs with Dunnett’s test for multiple comparisons was used to
compare between site differences relative to control (lactated Ring-
er’s) at each phase of the protocol. An a priori power analysis was
conducted where we determined that seven subjects would be suffi-
cient to detect a 10% differences in %CVCmax, between treatment
sites with a standard deviation of the difference at 8% (determined
from our previously published data) (5, 37, 45), a   0.80, and
ɑ  0.05. The interday reproducibility of SkBF measured using LDF
is considered acceptable when normalized to maximal values
(%CVCmax); however, due to the recognized variability in baseline
SkBF compared with the LH plateau, a 10% difference in %CVCmax
was determined as a physiologically meaningful difference (45).
Effect size (Cohen’s d) is reported for mean differences. Interpretation
of effect size followed the convention of Cohen: 0.2, 0.5, and 0.8
corresponding to a “small,” “medium,” and “large” effect size, re-
spectively (9).
RESULTS
Eight (4 men, 4 women) young, healthy subjects (age:
25  1 yr) participated in this study, all of whom were nono-
bese (BMI: 25.1  1.4 kg/m2) and normotensive (MAP:
85  3 mmHg).
As expected, no differences were observed between sites
at baseline 1 (lactated Ringer’s at all sites, P  0.14; data
not shown). Figure 1 illustrates perfusion of solution vehi-
cles at baseline 2 (local temperature clamped at 34°C). Cuta-
neous vascular conductance (%CVCmax) was greater at the
SCB-HCl site relative to control [lactated Ringers: 9.67 (95%
confidence interval: 7.81, 11.53), SCB-HCl: 21.52 (13.27,
29.76) %CVCmax; P  0.03] and the effect size was large
(1.66). %CVCmax was similar between control and both the
ethanol site [13.12 (9.91, 16.32) %CVCmax; P  0.11] and
DMSO site [14.75 (6.56, 22.95) %CVCmax; P  0.31].
During the standardized LH protocol to 42°C, the plateau in
SkBF was similar between all sites (Fig. 2, all P  0.05).
Figure 3 depicts absolute maximal vasodilation (expressed as
CVC: flux/mmHg) obtained during perfusion of SNP and
simultaneous 43°C local heat, which did not differ between
sites (all P  0.05). The solution vehicles were analyzed for
ion composition (Table 1) with the only notable difference
being the higher Na and Cl concentrations in the SCB-HCl
solution.
DISCUSSION
The main findings from the present study were that 1) a SCB
buffer perfused at physiological pH (following addition of
HCl) increased cutaneous blood flow at baseline relative to
lactated Ringer’s (control), whereas 2% DMSO and 0.02%
ethanol did not; and 2) perfusion of the vehicle solutions
SCB-HCl (pH 7.4), 2% DMSO, or 0.02% ethanol did not alter
SkBF responses vs. the control site during 42°C LH or maxi-
mal vasodilation. These findings are methodologically impor-
tant for delivering pharmacological agents with low aqueous
solubility via microdialysis by using these solubilizing agents
during investigation of cutaneous vascular function.
In the present study, the independent effects of three vehicle
solutions on SkBF responses were determined during a stan-
dard LH protocol. Vehicle solutions were selected based on
their common utility as solubilizing agents for effective deliv-
ery of pharmacologics with low aqueous solubility or stability.
Addition of HCl for delivery of buffer solutions at physiolog-
ical pH is important for subject comfort and safety, and to
avoid independent effects of local pH shifts on vascular func-
tion (27). Baseline vasodilation was observed with perfusion of
SCB-HCl, but not 2% DMSO or 0.02% ethanol through the
skin of young, healthy men and women. This baseline vasodi-
lation is an important finding with relevance to data interpre-
tation and normalization. If laser Doppler flux data are nor-
malized to baseline, as they are in many vasoconstriction data,
the differences in baseline can potentially confound the inter-
pretation of the data. Additionally, if the dilation from this
Fig. 1. Baseline vasodilation (means  SE) during perfusion of investigational
substances. Vasodilation was significantly greater with perfusion of sodium
carbonate-bicarbonate–hydrochloric acid (SCB-HCl) compared with control;
n  8 subjects; *P 	 0.05 compared with control site. Cutaneous vascular
conductance (CVC: flux per mean arterial pressure) expressed as a percentage
of site specific maximum (%CVCmax).
Fig. 2. Vasodilation (means  SE) during local heating to 42°C. Vasodilation
was not different from control with any solubilizing agent; n  8 subjects.
Fig. 3. Maximum vasodilation (expressed as absolute CVC; means  SE) at
each site. Maximum vasodilation was not different from control with any
solubilizing agent; n  8 subjects.
Table 1. Vehicle ionic composition
Vehicle Sodium, mmol/l Potassium, mmol/l Chloride, mmol/l
Lactated Ringer’s 123.0  0.0 3.8  0.0 104.0  0.0
DMSO 132.0  0.0 4.1  0.0 104.0  0.0
Ethanol 123.3  0.3 3.8  0.0 104.0  0.0
SCB-HCl 244.0  0.0 3.6  0.0 155.3  0.3
Values are means  SE. SCB-HCl, sodium carbonate-bicarbonate–hydro-
chloric acid.
buffer and a pharmacological agonist (such as endothelin
receptor antagonists including sulfisoxazole and PD-156707)
are additive, differences in vasodilation between a buffered and
a nonbuffered microdialysis site may not be mediated entirely
by the selected pharmacological agonist, but in part from the
presence of the buffer. A “vehicle control” site, with continu-
ous perfusion of the vehicle solution (drug free), should there-
fore be included in experimental protocols to assess the inde-
pendent effects at all stages of the protocol.
A small number of studies have considered the independent
effects of specific vehicle solutions on vascular function, yet
none have directly compared the effects of different vehicles.
In contrast to the present data, DMSO has been shown to cause
mild cutaneous vasodilation at thermoneutral baseline (33°C),
which is likely due to the use of concentrations 2% (7, 31,
36, 48). Animal studies using rat aortas exposed to increasing
concentrations of DMSO (0.1–3%) demonstrated increased
cGMP and significant increases in vasodilation with 3%
DMSO only (28). DMSO-induced vasodilation was inhibited
with addition of the nonspecific NOS inhibitor nitro-L-arginine
methyl ester (L-NAME) and with removal of the rat aorta
endothelium, collectively indicating DMSO to act via endothe-
lium-derived NO-dependent mechanisms in a rat model (28).
The use of 2% DMSO, as in the present study, has shown no
significant effect on SkBF (33), yet concentrations of 3–5%
DMSO have consistently shown minor vasodilatory properties
when delivered in vivo via microdialysis in the human cuta-
neous circulation (7, 31, 36). Kellogg and colleagues (31)
included a 5% DMSO (vehicle control) site throughout all
experimental protocols and observed significant vasodilation at
normothermic baseline (10  2%CVCmax), but no significant
differences vs. LR during whole body cold (3 min, 18°C water
perfused suit) or heat stress conditions (48°C water perfused
suit, 1°C
 core temperature). Similar results have been ob-
served by other laboratories using 5% DMSO (7) and 3%
DMSO (36), suggesting 5% DMSO may cause baseline
cutaneous vasodilation but no alteration of thermoregulatory
responses. Notably, during a separate LH protocol, Kellogg et
al. (31) observed no significant differences in SkBF between
5% DMSO and LR sites at baseline (Tsk 34°C; DMSO
28  5% vs. LR 27  5%CVCmax) or a standard LH protocol
to 41°C (DMSO 88  7% vs. 83  9%CVCmax). The 34°C
baseline Tsk may have masked the small vasodilatory effects of
5% DMSO observed at thermoneutral baseline (Tsk 33°C),
which highlights the need for careful consideration of baseline
conditions in experimental design. Alternatively, a lower con-
centration of a drug of interest may be dissolved in a lower
concentration of DMSO (33) or in an alternative vehicles that
does not elicit vasodilation, provided the required physiologi-
cal effect is achieved. For example, following preliminary
studies utilizing 5% DMSO, Wong and Fieger (48) selected 20
mM capsazepine dissolved in 90% propylene glycol and 10%
LR solution rather than pursuing higher concentrations of
capsazepine requiring DMSO.
In the present study, unlike baseline CVC, no change in
LH-induced vasodilation or maximal vasodilation was ob-
served with any of the vehicle solutions. These findings are
consistent with other studies using higher concentrations of
DMSO (3–5%) during similar protocols (7, 31, 36). The
similarity in local thermal hyperemia between sites suggests
that the SCB-HCl buffer augments only baseline dilation and
has no significant effect when SkBF is elevated by an agonist.
As hypothesized, 0.02% ethanol had no significant effect on
SkBF at any stage of the protocol and is therefore a suitable
solubilizing agent at such concentrations. Ethanol is a water-
soluble organic solvent commonly used as a solubilizing agent,
but has shown mixed effects on vascular function. Ethanol has
been shown to inhibit transient receptor potential channel 8
(TRPM8) in animal models and human cell cultures (2, 47),
while causing arterial vasodilation via TRPV1 receptors in
both human and animal isolated vessel studies (20). In human
in vivo studies, Craighead et al. (11) observed an attenuated
menthol-mediated dilation when dissolved in a vehicle solution
containing ethanol vs. LR (preliminary data), supporting the
potential inhibitory effects of ethanol on cold-menthol TRPM8
receptors and alterations in cutaneous vascular function. Effi-
cacious administration was subsequently achieved using a
heating-stirring plate to aid menthol solubility, and may be
considered as an alternative approach to solubilizing agents
when feasible. Overall, these findings indicate that these vehi-
cle solutions, at the concentrations utilized in this study, do not
interfere with endothelial function in the cutaneous circulation
and may be utilized without fear of alterations in microvascular
function obscuring results.
The similarity in maximal vasodilation observed between all
sites is important, but not unexpected. Maximum vascular
conductance (or minimum vascular resistance) represents the
maximum ability of the vasculature to dilate, and is an index of
vascular structure (8, 12, 17, 42, 44). It is extremely unlikely
that the acute use of a solubilizing agent would induce any
alteration in microvascular structure over the short duration of
a single microdialysis experiment. As anticipated, we observed
no increase in maximum CVC with any of the solubilizing
agent used. Solubilizing agents could theoretically cause a
functional impairment that would attenuate maximum CVC.
We observed no difference between our solubilizing agents and
control, indicating that no functional decrements occurred. It is
important that maximum CVC was not altered by any of the
utilized solubilizing agents, as maximum CVC is used for data
normalization and alteration of this value would affect all the
measures of %CVCmax within a microdialysis site.
Analysis of the ionic composition of the vehicle solutions
indicated a higher concentration of sodium and chloride in the
SCB-HCl solution vs. all other vehicle solutions, but no dif-
ference in potassium. One possible mechanism mediating the
augmented baseline SkBF with SCB-HCl perfusion may be an
alteration in the cell membrane potential resulting from in-
creased interstitial sodium. During LH, the intensity of the
stimulus may have overridden any baseline effect of sodium on
cell membrane potential, resulting in no significant impact on
SkBF during heating. Furthermore, chloride ion concentration
was slightly higher in the SCB-HCl vehicle solution, which has
the potential to bring the membrane potential closer to resting
state. Overall, the effect of the higher Na and Cl concen-
trations appear to have affected only baseline vascular func-
tion. Notably, microdialysis perfusion of a hypertonic saline
(3% NaCl) has been observed to elicit acute microvascular
dysfunction when compared with normal saline, reducing the
initial peak and LH plateau during the same standardized LH
protocol as the present study (14). When co-infused with the
nonspecific NOS inhibitor L-NAME, a reduced NO contribu-
tion to the LH plateau was observed at the hypertonic vs.
normal saline site, suggesting a role of sodium in the attenuated
cutaneous vascular response, potentiality mediated via reduced
NO production or availability. The high sodium chloride con-
centration used by DuPont and colleagues (14) may explain the
disparity in results compared with the present data, but does
provide some evidence that altering interstitial sodium concen-
tration may alter vascular responses.
Our data, demonstrating no differences between vehicle
solutions in maximal CVC, are important with relevance to
data interpretation using these techniques. Data obtained via
laser Doppler flowmetry are subject to multiple possible data
normalization schemes. It is standard to normalize the arbitrary
red cell flux units measured via laser Doppler flowmetry to
mean arterial pressure to account for changes in driving pres-
sure. When cutaneous vasodilation is induced, either through
pharmacological (acetylcholine, SNP) or physiological (local
or whole body heating) stimuli, the data are generally ex-
pressed as a percentage of maximum conductance (%CVCmax)
elicited by high local temperature (43°C) (22, 41), a high
dose of SNP (28 mM) (6, 19, 29), or a combination of the
two (1, 15, 16, 21). Normalizing to maximum conductance
helps to account for variance in local vessel density within the
relatively small field of view (~1 mm2) of individual laser
Doppler probes (4) and for comparing between different mea-
surement sites.
Recommendations for the use of solubilizing agents for
delivery of pharmacologics via cutaneous microdialysis. Inves-
tigators should consider the following points for experimental
design and data analysis when vehicle solutions other than LR
are used: 1) when possible, identify pharmacologics with high
aqueous solubility for delivery with LR, low molecular weight,
and high stability at physiological pH; 2) consider using a
heating-stirring plate to improve solubility of a drug as an
alternative to a solubilizing agent if efficacious delivery is
possible, 3) ideally, a vehicle control site should be used
throughout the protocol to confirm the effects of the solubiliz-
ing agent at all stages, 4) if a vehicle control site is not
methodologically possible, vehicle solutions should be per-
fused at baseline before drug delivery to determine the inde-
pendent effects of the vehicle/solubilizing agent; and 5) inves-
tigators must acknowledge baseline shift and consider appro-
priate normalization strategies.
Limitations. A limitation to this study is that we examined a
group of young, healthy subjects. In this population, the SkBF
response to LH is likely limited by a ceiling effect as CVC
reaches near maximum values. Therefore augmentation of
conductance by any of the employed solubilizing agents may
not be observable in this healthy population. It remains to be
seen whether SCB-HCl (or any of the other agents) alters the
SkBF response to LH in older or clinical populations that
exhibit impaired endothelial function and attenuation of SkBF
or during other protocols. Additionally, all subjects adhered to
the usual conditions for experimental testing (i.e., no alcohol or
caffeine for 12 h before testing); however, menstrual cycle
phase was not controlled for during the present study. A further
consideration is the limited generalizability of the present data
based on the type of microdialysis probe used, molecular
weight cutoff (MWCO), and the perfusion rates employed. In
the present study, a polyacrylonitrile (PAN) probe membrane
with a 30-kDa MWCO and perfusion rates of 2 l/min were
utilized. Notably, the delivery characteristics may be altered
when using different probe membrane materials, for example,
cuprophane (regenerated cellulose), polycarbonate, or poly-
ethersulfone, differing MWCO (noting that the effective
MWCO is typically only 20–30% of the reported MWCO),
varying probe lengths, and perfusion rates. This reinforces the
importance of including a vehicle control site throughout an
experimental protocol. Finally, a power calculation was per-
formed to detect a physiologically meaningful difference of
10%CVCmax between vehicles sites; however, we were under-
powered to detect smaller differences.
Conclusions. The present study identified that a basic buffer
solution administered at physiological pH (SCB-HCl), in-
creased baseline CVC compared with lactated Ringer’s solu-
tion. However, no change in baseline conductance was ob-
served with DMSO (2%) or ethanol (0.02%). Neither local
thermal hyperemia nor maximum CVC were altered by the use
of any of the solubilizing agents. These data suggest that
baseline shifts in CVC when interpreting data must be ac-
counted for when buffer solutions are used to improve micro-
dialysis perfusate solubility. Importantly, our data indicate that
DMSO and ethanol, at the concentrations used in the present
study, did not independently alter cutaneous vascular function
during a commonly utilized LH protocol. These findings fur-
ther highlight the utility of intradermal microdialysis, coupled
with laser Doppler flowmetry, as an effective, reproducible,
and minimally invasive technique to assess cutaneous micro-
vascular responses.
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